Skip to Content
Global News Select

Calliditas Therapeutics Shares Drop 10% After PDUFA Date Pushed Back

By Chris Wack


Calliditas Therapeutics AB shares were down 10% to $22.16 after the company said the U.S. Food and Drug Administration has extended the Prescription Drug User Fee Act goal date for its New Drug Application seeking accelerated approval for Nefecon to Dec. 15.

Volume for the stock was $156,000 shares at 12:40 p.m. ET, compared to its 65-day average volume of 27,000 shares. The stock hit its 52-week low of $20.50 on Aug. 20.

In March, Calliditas filed for FDA approval using the Accelerated Approval Program, based on the proteinuria endpoint as previously discussed with the Agency, reflecting data from the 200 patients in Part A of its trial.

In its review of the NDA, the FDA has requested further analyses of the trial data which the company has provided to the FDA. The FDA has classified these analyses as a major amendment to the NDA, extending the PDUFA goal date to December.


Write to Chris Wack at


(END) Dow Jones Newswires

September 15, 2021 13:02 ET (17:02 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

  • Verify your identity, personalize the content you receive, or create and administer your account.
  • Provide specific products and services to you, such as portfolio management or data aggregation.
  • Develop and improve features of our offerings.
  • Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.